<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=35476375865279447&ev=PageView&noscript=1"/>

Alkem Laboratories Limited

NSE: ALKEM · Lot size: 125

Alkem Laboratories Limited Open Interest & PCR Analysis

5,679Updated 21 Apr 2026, 01:26 pm IST
PCR
0.61
Bearish signal
Max Pain
5,500
Spot above by ₹179
Total CE OI
358K
Call writers
Total PE OI
218K
Put writers
OI Buildup Signal
Neutral
Price movement < 0.3% threshold
Put-Call Ratio Gauge
0 — Bearish1.0 — Neutral2.0+ — Bullish

Data as of 2026-04-21

Frequently Asked Questions

What is Alkem Laboratories Limited PCR (Put-Call Ratio) today?
Alkem Laboratories Limited's current PCR is 0.61. A PCR above 1.2 is considered bullish (more put writing = floor support); below 0.8 is bearish; 0.8–1.2 is neutral. Alkem Laboratories Limited's PCR of 0.61 indicates bearish sentiment.
What is Alkem Laboratories Limited OI buildup type today?
Alkem Laboratories Limited is currently showing neutral positioning with no significant directional bias. This is determined by comparing today's price change direction with the direction of total OI change — using the standard F&O buildup classification framework.
What is total CE and PE open interest for Alkem Laboratories Limited?
Alkem Laboratories Limited has total CE (call) OI of 357500 contracts and total PE (put) OI of 218000 contracts for the nearest expiry. The PCR is 0.61.
How is open interest analysis useful for Alkem Laboratories Limited trading?
OI analysis for Alkem Laboratories Limited helps identify institutional positioning. High CE OI at a strike = call writers defending that level (resistance). High PE OI = put writers defending that level (support). The buildup type tells you whether smart money is building fresh positions (bullish/bearish) or exiting existing ones.
What is the max pain for Alkem Laboratories Limited?
Alkem Laboratories Limited's max pain is ₹5,500 — the strike price where option writers (sellers) collectively suffer the least financial loss at expiry. The current spot price vs max pain deviation guides near-term directional bias into expiry.